

ORIGINAL RESEARCH

Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status

Ravinder Mohan, MD, PhD, Hind Beydoun, PhD, Myra L. Barnes-Ely, MPH, LaShonda Lee, MPH, John W. Davis, MD, Raymond Lance, MD, and Paul Schellhammer, MD

Background: Cancer-specific mortality is projected to be only 1% in 15 years in approximately 75% of patients with screen-detected localized prostate cancer (LPC). Nearly 94% of patients choose treatment even though treatment damages health-related quality of life. No data are available regarding what survival benefit patients expected from treatment.

Objectives: A self-administered mailed survey was sent to 184 men with newly diagnosed LPC to query patients about expected survival with treatment versus observation.

Results: More than 90% of patients had at least a high school education and a ninth-grade health literacy. In addition, 68% patients had income of \geq \$50,000. Mean cancer grade was 6.6. Twenty-three patients chose observation and 161 patients chose surgery or radiotherapy. Mean comorbidity adjusted life expectancy (CALE) without the cancer was 22.9 years. Without cancer treatment, 15.2% of patients expected to live <5 years, 48.8% 5 to 10 years, 33.5% 11 to 19 years, and 2.4% \geq 20 years. With treatment, survival expectations were <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, and \geq 20 years in 62.9% of patients. Age, prostate-specific antigen level, CALE, anxiety, depression, and social support were factors that predicted differences between CALE and patient survival expectations with and without treatment.

Conclusion: LPC patients grossly underestimated their life expectancy without treatment and grossly overestimated the survival benefit of treatment. (J Am Board Fam Med 2009;22:247–56.)

Although around 80% of men aged 80 years and older and 15% to 30% of men aged 50 years and older have microscopic undiagnosed prostate cancer found at autopsy, only 3% men die because of prostate cancer.¹ Increasing prostate-specific antigen (PSA) screening at younger ages has increased overdiagnosis² and overtreatment³ of localized prostate cancer (LPC). More than 90% of US pa-

tients currently diagnosed with prostate cancer have LPC and approximately 94% of patients with LPC choose treatment.⁴ Based on data from leading studies, a model had recently projected only a 0% to 2% 15-year mortality from low-grade (Gleason score <7) screen-detected LPC in men aged 55 to 74 years if they chose observation instead of treatment.⁵ By consensus, urologists and radiation oncologists recommend treatment for LPC if a patient has a further 10-year life expectancy⁶ (the 10-year rule⁷) regardless of cancer grade, even though no randomized trials have shown that treatment can improve survival in patients in whom the cancer was screen-detected. National guidelines by the American Cancer Society and the National Comprehensive Cancer Network (NCCN) also recommend treatment for most patients.⁸ However, in the review by Zeliadt et al,⁹ different studies had found that patients rate the sexual, urinary, and bowel side effects of treatment to be just as important as the potential benefit in survival; that if risks and benefits of treatment were explained with-

This article was externally peer reviewed.

Submitted 17 September 2008; revised 29 January 2009; accepted 2 February 2009.

From the Department of Family and Community Medicine (RM, LL); the Graduate Program in Public Health (HB); the Department of Pediatrics (MLB); and the Department of Urology (RL, PS), Eastern Virginia Medical School, Norfolk; and the Department of Urology, MD Anderson Cancer Center, Houston, TX (JWD).

Funding: Norfolk Foundation and the US Health Resources Service Administration Department of Health and Human Services, grant no. 2002737.

Conflict of interest: none declared.

Corresponding author: Ravinder Mohan, MD, PhD, Associate Professor, Department of Family and Community Medicine, Eastern Virginia Medical School, 825 Fairfax Avenue, Norfolk, VA 23507 (E-mail: mohanr@evms.edu).

out bias, 75% of patients chose a lower radiation dose despite a lower predicted survival; that 90% of physicians but fewer than 20% of patients ranked the effect of treatment on survival as one of their top 4 concerns; and that patients who chose treatment believed that treatment was guaranteed to improve survival. At a median of 6 years after treatment, health-related quality of life (HRQOL) of treated patients was worse than that of control patients.¹⁰ Many patients regretted that they chose treatment.¹¹

To our knowledge, no studies of patient-physician communication have examined patients' anticipated survival benefit of treatment. Without data from randomized trials in screen-detected patients, it is difficult to counsel patients regarding their survival with and without treatment. Even with the use of multifactorial models, accuracy of predicted survival is 75% or lower.¹² Physicians are also poor at estimating baseline comorbidity adjusted life expectancy (CALE), which is critical in making an informed decision.¹³ Thus, patients may accept a treatment recommendation not knowing what their baseline CALE is, how much the newly diagnosed cancer could reduce it, or how effectively treatment could minimize that reduction. Current overtreatment of LPC might be because patients do not understand the pros and cons of treatment.

In this study we surveyed newly diagnosed patients about their anticipation of survival with and without treatment. By estimating their baseline CALE without considering the newly diagnosed cancer, we calculated their perceived decrease in longevity with observation (PDLO), and their perceived increase in longevity with treatment (PILT) for the cancer.

Methods

We surveyed patients who had been newly diagnosed with LPC (stages T1a to T2c) in the preceding 6 months, had met with their urologist after the diagnosis, were scheduled to receive treatment or observation, and had not yet been treated with surgery or radiation. Patients with dementia, or those who could not read, write, or understand English, were excluded. All patients were recruited from a large, private urology practice in Norfolk, Virginia. Staff at this practice systematically contacted patients newly diagnosed with LPC between March 2005 and November 2007 regarding their

interest in participation in a self-administered mailed survey. Two concomitant pretreatment self-administered surveys were used. The first survey asked patients about expectations of survival with and without treatment, comorbid diseases, mood, social support, satisfaction with life, health, and education by physicians about treatment options. A list of health-related words in a closed envelope was mailed with the survey. Patients were requested to open the envelope and read these words on the telephone to a research assistant. This was done to estimate patient health literacy by using a brief version of the Rapid Estimation of Health Literacy in Medicine scale.¹⁴ Patients were given a \$10 stipend for completing this survey. A second pretreatment survey was a part of a longitudinal follow-up by urologists to evaluate generic HRQOL, prostate cancer related symptoms, and fear of cancer recurrence. The study methods were reviewed and approved by an Institutional Review Board.

Measures

The Charlson Comorbidity Index (CCI) is a validated measure of comorbidity. We used a patient self-reported CCI scale that asked about the presence and severity of 12 chronic conditions; the Prostate Cancer Outcomes Study used this CCI version.¹⁵ Score categories are 0, 1, 2, and 3 or more diseases.

The NCCN practice guidelines had recommended, for the first time in 2007,⁸ that the health-adjusted life expectancy of LPC patients can be estimated by weighting age-based life expectancy by 1.5 for patients in the highest health quartile, using no weighting for patients in the middle 2 health quartiles, and weighting by 0.5 for patients in the lowest health quartile. We used comorbidity scores as surrogate markers of health status because comorbidity is the main determinant of life expectancy in older patients,¹⁶ and the most important prognostic factor for patients with LPC who are <75 years old is the comorbidity score.¹⁷ We categorized patients into health quartiles by using their CCI score (0 disease score = highest health quartile; 1 or 2 disease score = middle 2 health quartiles; ≥ 3 disease score = lowest health quartile). Our basis of equating a 1 or 2 disease score with the middle 2 health quartiles was that almost half (49%) of the 3173 patients newly diagnosed with LPC in a Prostate Cancer Outcomes Study¹⁵ had a disease score of 1 or 2, and almost half

(55.5%) of our patients had a disease score of 1 or 2. Both studies used the same version and scoring of the CCI. Patients were placed in 4 CALE categories: <5 years, 5 to 10 years, 10 to 20 years, and >20 years. These 4 categories were scored, respectively, from 1 to 4.

Patients were asked the following 2 questions: “How long do you expect you will live *without* any treatment for prostate cancer?” (Q1) and “How long do you expect you will live after treatment for prostate cancer?” (Q2). The possible responses to both questions were grouped into 4 categories (similar to the CALE categories): <5 years, 5 to 10 years, 10 to 20 years, and >20 years. These 4 categories were also scored from 1 to 4, respectively.

Based on Q1, Q2, and CALE scores, we calculated the patient’s PDLO (which is CALE category score minus Q1 category score) and the patient’s PILT (which is Q2 category score minus Q1 category score). A PDLO of ≥ 10 years is at least a 2-category difference between the CALE category and the Q1 category; this is only possible if the CALE was >20 years and the Q1 response was 5 to 10 years or if the CALE was 10 to 20 years and the Q1 response was <5 years. Similarly, a PILT of ≥ 10 years indicates that the response to Q2 was 10 years or more than the response to Q1. We conducted ordinal logistic regression analyses to identify the main sociodemographic, health, and cancer characteristics that could predict PDLO and PILT of ≥ 10 years.

The following validated self-administered scales were used. (1) The Short-Form 36 (SF-36, version 2) measures generic HRQOL; we calculated physical component summary and mental component summary scores from SF-36 data.¹⁸ (2) The Prostate Cancer Index measures urinary, sexual, and bowel symptoms and how much they bother the patient.¹⁹ (3) The Duke Activity Status Index²⁰ measures functional capacity in metabolic equivalents; this scale asks patients whether they could perform 12 activities which have different levels of exertion. (4) The Hospital Anxiety and Depression Scale measures the presence and severity of anxiety and depression.²¹ (5) The Fear of Cancer Recurrence Scale measures the fear of possible cancer recurrence.²² (6) The Medical Outcomes Study Social Support Survey measures social support in an overall score that includes multidimensional sub-

scores.²³ (7) The Delighted-Terrible Seven Faces Scale²⁴ was used to measure patient satisfaction with life, health, and with education given by physicians about treatment options for LPC. (8) The Rapid Estimation of Health Literacy in Medicine scale, discussed earlier, measures health literacy; this was the only scale administered by telephone.¹⁴

Statistical Analyses

Frequencies and relative frequencies were used to describe categorical variables. Continuous variables were described using the mean, median, and SD. χ^2 tests, Fisher’s exact test, and independent sample *t* tests were used to examine bivariate associations. Unadjusted and adjusted odds ratios (ORs) and their 95% CIs were estimated using ordinal logistic regression analysis. Sociodemographic and health factors that were found to be associated with PDLO and PILT in the bivariate analysis at an α level of 0.20 were kept in the multivariate models. All analyses were performed using SAS software (version 9.1, SAS Institute, Inc., Cary, NC).

Results

Surveys were mailed to 430 patients newly diagnosed with LPC, but 69 patients had already started treatment by the time the patients received the surveys, 3 patients never received the surveys, and 2 patients were found to be ineligible to participate because their cancer was not localized to the prostate. Of the 356 remaining patients, 104 patients did not return the survey because they were “not interested” in participating and 68 patients who did not return the surveys did not give a reason for not participating or could not be contacted. One hundred eighty-four of 356 patients (survey response rate of 52%) completed and returned the first pretreatment survey; 23 of these 184 patients (12.5%) patients chose observation.

Table 1 shows a demographic comparison of patients who chose treatment or observation. Mean patient age was 61.5 years, and most patients reported college education and a family income of >\$50,000. Table 2 shows a comparison of patients who chose treatment or observation by cancer grade, PSA, life expectancy by age, and comorbidity scores. Mean Gleason grade was 6.6. Table 2 also includes a comparison of these patient groups by SF-36 scores (Physical Component and Mental

Table 1. Comparison of Sociodemographic Characteristics of Patients with Localized Prostate Cancer who Chose Treatment* and Observation†

Characteristic	Overall (n [%])	Treatment (n [%])	Observation (n [%])	<i>P</i> ‡
Age (years)	n = 184	n = 161	n = 23	
<60	71 (38.6)	68 (42.2)	3 (13.0)	
60–70	91 (49.5)	81 (50.3)	10 (43.5)	
>70	22 (11.9)	12 (7.5)	10 (43.5)	<.0001
Mean ± SD	61.5 ± 7.9	60.6 ± 7.6	68.2 ± 5.9	<.0001
Race	n = 184	n = 161	n = 23	
African American	26 (14.1)	26 (16.2)	0 (0.0)	
White	158 (85.9)	135 (83.9)	23 (100)	.05§
Education	n = 180	n = 157	n = 23	
<High school	7 (3.9)	7 (4.5)	0 (0.0)	
High school	65 (36.1)	56 (35.7)	9 (39.1)	
College	108 (60.0)	94 (59.9)	14 (60.9)	.58
Health literacy	n = 173	n = 150	n = 23	
Below 6th grade	1 (0.6)	1 (0.7)	0 (0.0)	
6th–9th grade	16 (9.3)	15 (10.0)	1 (4.4)	
>9th grade	156 (90.2)	134 (89.3)	22 (95.7)	.63
Family income	n = 179	n = 156	n = 23	
Low (<\$50,000)	57 (31.8)	50 (32.0)	7 (30.4)	
High (≥\$50,000)	122 (68.2)	106 (67.9)	16 (69.6)	.88

*Treatment patients had either surgery or radiotherapy.

†Observation patients had neither surgery nor radiotherapy.

‡Unless otherwise specified, statistical significance is for χ^2 test (categorical variables) or independent samples *t* test (continuous variable).

§Fisher's exact test.

Component Scores), as well as the urinary, sexual, and bowel function scores of the 144 of 184 patients who had also returned the second pretreatment survey. Table 3 shows a comparison of patients who chose treatment or observation by CALE, anxiety and depression, function capacity, social support, and satisfaction. Mean CALE was 22.9 years.

Table 4 shows the baseline CALE for the 184 patients and the responses of 170 of the 184 patients who had answered questions about their perceived life expectancy without treatment (Q1) and with treatment (Q2) of the cancer. Without treatment, perceived life expectancy was <5 years in 15.2%, 5 to 10 years in 48.8%, 11 to 19 years in 33.5% and ≥20 years in 2.4% of the patients. With treatment, it was <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, and ≥20 years in 62.9% of the patients. By contrast, baseline CALE was <5 years in 0.5%, 5 to 10 years in 2.2%, 11 to 19 years in 36.4%, and ≥20 years in 60.9%. A total of 170 patients had data on CALE, Q1, and Q2. As compared with CALE, 65 (38.2%) of these 170 patients expected

survival to decrease by ≥10 years without treatment. As compared with their perceived survival without treatment, 81 (47.6%) of 170 patients expected their survival to increase by ≥10 years with treatment. Of the 108 patients with a baseline CALE of >20 years, only 2 (1.9%) expected to live beyond 20 years without treatment whereas 84 (77.8%) expected to live beyond 20 years with treatment (data not shown). Neither of these perceptions was significantly related to whether the patients chose treatment or observation. However, to a statistically insignificant extent, patients who chose treatment were more likely than observation patients to expect a ≥10-year reduction in survival without treatment (50% vs. 33.3%, χ^2 test; *P* = .26) and a ≥10-year increase in survival with treatment (39.9% vs. 16.7%, Fisher's exact test; *P* = .13).

Tables 5 and 6 present ordinal logistic regression models for PDLO and PILT. Age, CALE, depression, and anxiety scores predicted both PDLO and PILT. Furthermore, PSA level predicted PDLO, whereas social support predicted PILT.

Table 2. Comparison of Patients who Chose Treatment and Observation by Prostate Cancer-Related and Health Factors

Factors	Overall (n [%])	Treatment (n [%])	Observation (n [%])	<i>P</i> *
Gleason Grade	n = 184	n = 161	N = 23	
2–4	0 (0.0)	0 (0.0)	0 (0.0)	
5–6	103 (55.9)	84 (52.1)	19 (82.6)	
7	62 (33.7)	60 (37.3)	2 (8.7)	
8–10	19 (10.3)	17 (10.6)	2 (8.7)	0.02
Mean ± SD	6.6 ± 0.7	6.6 ± 0.7	6.2 ± 0.7	0.02
Prostate-specific antigen test	n = 183	n = 161	n = 23	
≤10	159 (86.9)	139 (86.3)	21 (91.3)	
>10	24 (13.1)	22 (13.7)	2 (8.7)	0.74
Mean ± SD	6.7 ± 5.3	6.8 ± 5.5	5.6 ± 3.4	0.14
Life expectancy by age (years)	n = 183	n = 160	N = 23	
<10	4 (2.2)	2 (1.3)	2 (8.7)	
10–20	104 (56.8)	86 (53.8)	18 (78.3)	
≥20	75 (40.9)	72 (45.0)	3 (13.0)	0.002*
Comorbidity score	n = 184	n = 161	N = 23	
0	74 (40.2)	66 (40.9)	8 (34.8)	
1	75 (40.8)	67 (41.6)	8 (34.8)	
2	27 (14.7)	23 (14.3)	4 (17.4)	
≥3	8 (4.4)	5 (3.1)	3 (13.0)	0.16
Mean ± SD	0.9 ± 1.0	0.83 ± 0.96	1.26 ± 1.5	0.18
Short Form-36 subscales				
Physical component summary	n = 142	n = 134	n = 8	
Mean ± SD	54.5 ± 7.6	54.5 ± 7.2	52.6 ± 12.3	0.66
Mental component summary	n = 142	n = 134	n = 8	
Mean ± SD	44.1 ± 6.8	43.9 ± 6.9	46.4 ± 4.5	0.29
Prostate cancer index				
Urinary	n = 141	n = 132	n = 9	
Mean ± SD	90.2 ± 16.9	90.1 ± 17.4	91.3 ± 9.3	0.83
Bowel	n = 142	n = 133	n = 9	
Mean ± SD	88.8 ± 12.5	88.5 ± 12.8	92.9 ± 4.5	0.03
Sexual	n = 137	n = 128	n = 9	
Mean ± SD	57.7 ± 29.9	57.8 ± 30.4	55.4 ± 23.8	0.82
Urinary Bother	n = 144	n = 135	n = 9	
Mean ± SD	86.1 ± 23.0	85.9 ± 23.4	88.9 ± 18.2	0.71
Bowel Bother	n = 144	n = 135	n = 9	
Mean ± SD	92.5 ± 17.5	92.0 ± 17.9	100 ± 0.0	<0.0001
Sexual Bother	n = 142	n = 133	n = 9	
Mean ± SD	65.8 ± 36.8	65.4 ± 36.8	72.2 ± 38.4	0.59
Fear of cancer recurrence	n = 141	n = 133	n = 8	
Mean ± SD	10.7 ± 3.8	10.7 ± 3.7	10.9 ± 4.5	0.92

Discussion

Prostate cancer is the most common solid cancer in men. Younger patients make up a fast-growing population that is being screen-detected and treated for low-risk LPC.²⁵ To our knowledge, this is the first study to report the perceptions of newly diagnosed patients about how the cancer or its

treatment could affect their survival. The mean age of our patients (61.5 years) was similar to the range of 58 to 64 years of US patients currently undergoing radical prostatectomy.²⁶ The mean Gleason grade was 6.6 in our patients, similar to other series in which almost half of screen-detected cancers were “insignificant.”²⁷ By choosing treatment,

Table 3. Distribution of Men by Prostate Cancer-Related and Health Characteristics

Characteristic	Overall (n [%])	Treatment (n [%]) [*] **	Observation (n [%]) [†] ***	<i>P</i> [‡] *
Comorbidity adjusted life expectancy (CALE)				
All ages	184 (100)	161 (100)	23 (100)	
<5 years	1 (0.5)	0 (0)	1 (4.3)	
5–10 years	4 (2.2)	2 (1.2)	2 (8.7)	
11–19 years	67 (36.4)	52 (32.3)	15 (65.2)	
≥20 years	112 (60.9)	107 (66.5)	5 (21.7)	<.0001
Mean ± SD	22.9 ± 7.6	23.9 ± 7.3	16.4 ± 5.7	<.0001
Anxiety score				
	n = 183	n = 160	n = 23	
None/normal (0–7)	145 (79.2)	123 (76.9)	22 (95.7)	
Mild anxiety (8–10)	23 (12.6)	23 (14.4)	0 (0.0)	
Moderate anxiety (11–14)	12 (6.6)	11 (6.9)	1 (4.4)	
Clinical (15–21)	3 (1.6)	3 (1.9)	0 (0.0)	.18
Mean ± SD	5.1 ± 3.5	5.4 ± 3.5	2.8 ± 2.9	.0008
Depression score				
	n = 178	n = 156	n = 22	
None/normal (0–7)	172 (96.6)	150 (96.2)	22 (100)	
Mild depression (8–10)	4 (2.3)	4 (2.6)	0 (0.0)	
Moderate (11–14)	1 (0.6)	1 (0.6)	0 (0.0)	
Clinical (15–21)	1 (0.6)	1 (0.6)	0 (0.0)	.83
Mean ± SD	1.7 ± 2.3	1.7 ± 2.4	1.4 ± 1.7	.49
Functional capacity				
	n = 184	n = 160	n = 23	
Mild activities (<3 METs)	1 (0.5)	1 (0.6)	0 (0.0)	
Moderate activities (3–6 METs)	20 (10.9)	15 (9.3)	5 (21.7)	
Vigorous activities (≥6 METs)	163 (88.6)	145 (90.1)	18 (78.3)	.19
Social support				
	n = 183	n = 160	n = 23	
<50	7 (3.8)	6 (3.8)	1 (4.4)	
50–75	33 (18.0)	29 (18.1)	4 (17.4)	
75–100	143 (78.1)	125 (78.1)	18 (78.3)	.98
Satisfaction with Life				
	n = 178	n = 156	n = 22	
Delighted or highly satisfied	138 (77.5)	121 (77.6)	17 (77.3)	
Satisfied or lower	40 (22.5)	35 (22.4)	5 (22.7)	.97
Mean ± SD	6.0 ± 0.9	5.9 ± 0.9	6.1 ± 1.0	.64
Satisfaction with health				
	n = 178	n = 156	n = 22	
Delighted or highly satisfied	85 (47.8)	72 (46.1)	13 (59.1)	
Satisfied or lower	93 (52.3)	84 (53.9)	9 (40.9)	.26
Mean ± SD	5.0 ± 1.3	5.0 ± 1.3	5.4 ± 1.4	.19
Satisfaction with education by physician				
	n = 178	n = 156	n = 22	
Delighted or highly satisfied	141 (79.2)	126 (80.8)	15 (68.2)	
Satisfied or lower	37 (20.8)	30 (19.2)	7 (31.8)	.17
Mean ± SD	6.1 ± 0.9	6.1 ± 0.9	5.9 ± 1.1	.1

*Treatment patients had either surgery or radiotherapy.

[†]Observation patients had neither surgery nor radiotherapy.

[‡]Unless otherwise specified, statistical significance is for χ^2 test (categorical variables) or independent samples *t* test (continuous variable).

MET, metabolic equivalent.

these low-risk patients had accepted the treatment side effects in exchange for longer anticipated survival. Our questions were designed to find how much longer these patients expected to live by choosing treatment. These expectations were eval-

uated after the patients had discussed their treatment options with their urologists. Despite their mean baseline CALE of 22.9 years, without treatment, 26 of 170 patients expected to live <5 years and only 4 expected to live >20 years; with treat-

Table 4. Distribution of Men with Localized Prostate Cancer by Calculated Comorbidity Adjusted Life Expectancy

Expected Survival (years)	Baseline CALE Score (n = 184)	Q1 (n = 170)	Q2 (n = 170)
<5	1 (0.5)	26 (15.2)	1 (0.6)
5–10	4 (2.2)	83 (48.8)	11 (6.5)
11–19	67 (36.4)	57 (33.5)	51 (30.0)
≥20	112 (60.9)	4 (2.4)	107 (62.9)

Data provided as n (%).

CALE, comorbidity adjusted life expectancy; Q1, How long do you expect you will live without any treatment for prostate cancer?; Q2, How long do you expect you will live after the treatment of your choice for prostate cancer?

ment, only 1 expected to live <5 years and 107 patients expected to live >20 years.

What should these patients really be expecting? Nearly 86% of all patients diagnosed through PSA screening are not expected to die because of pros-

tate cancer.²⁸ The Connecticut Tumor Registry found that almost 20% of patients with Gleason grade ≥6 who chose observation died as a result of LPC during a period of 20 years.²⁹ However, all the Registry's patients had been clinically diag-

Table 5. Ordinal Logistic Regression Modeling for Perceived Decrease in Longevity with Observation (PDLO) among Men with Localized Prostate Cancer

	Unadjusted Effects			OR (95% CI)	Adjusted Effects OR (95% CI)
	PDLO ≤0*	PDLO = 1 [†]	PDLO ≥2 [‡]		
Age	25	62	83	1.08 (1.04–1.13)	1.01 (0.92–1.10)
PSA level	25	62	82	0.94 (0.88–1.00)	0.93 (0.86–1.00)
CALE	25	62	83	0.92 (0.88–0.96)	0.93 (0.84–1.02)
Anxiety score	25	62	83	0.88 (0.81–0.96)	0.96 (0.85–1.08)
Depression score	25	58	82	0.79 (0.67–0.93)	0.85 (0.69–1.04)

*A (PDLO) ≤0 (reference group) indicates that CALE and self-reported survival expectation without treatment are within the same range or CALE is less.

[†]A (PDLO) = 1 suggests that CALE exceeds self-reported survival expectation without treatment by one response category.

[‡]A (PDLO) ≥2 suggests that CALE exceeds self-reported survival expectation without treatment by at least 2 response categories (ie., about 10 years). All covariates in the ordinal logistic regression model are defined as continuous variables.

PDLO, perceived decrease in longevity with observation (categorized); PSA, prostate-specific antigen; CALE, comorbidity adjusted life expectancy; OR, odds ratio.

Table 6. Ordinal Logistic Regression Modeling for Perceived Increase in Longevity with Treatment (PILT) among Men with Localized Prostate Cancer

	Unadjusted effects			OR (95% CI)	Adjusted effects OR (95% CI)
	PILT ≤0*	PILT = 1 [†]	PILT ≥2 [‡]		
Age	18	87	65	1.08 (1.04–1.13)	1.09 (0.99–1.19)
CALE	18	87	65	0.93 (0.89–0.97)	1.02 (0.93–1.12)
Anxiety score	18	87	65	0.89 (0.82–0.98)	0.91 (0.81–1.02)
Depression score	18	83	64	0.93 (0.82–1.05)	1.06 (0.89–1.26)
Social support	18	87	65	1.01 (0.99–1.03)	1.00 (0.98–1.02)

*PILT ≤0 (reference group) indicates that CALE and self-reported survival expectation with treatment are within the same range or CALE is less.

[†]A (PILT) = 1 suggests that CALE exceeds self-reported survival expectation with treatment by one response category.

[‡]A (PILT) ≥2 suggests that CALE exceeds self-reported survival expectation with treatment by at least 2 response categories (ie., about 10 years). All covariates in the ordinal logistic regression model are defined as continuous variables.

PILT, perceived increase in longevity with treatment (categorized); CALE, comorbidity adjusted life expectancy; OR, odds ratio.

nosed; in contrast, patients diagnosed with screen-detected LPC are expected to have a longer survival because of a gain in lead time. Patients in another commonly cited natural history study³⁰ were also not diagnosed by PSA screening. A review³¹ found that only one randomized, high-quality trial³² could find a survival benefit of treatment, but in this trial 95% of patients had cancer that was clinically palpable (and not detected by PSA screening), putting this cohort in an intermediate- to high-risk category. A study of 44,630 men found a survival benefit of treatment,³³ but only 2.1% of the patient sample had died of prostate cancer. If adjusted for lead time provided by screening and also for the impairment of HRQOL that follows treatment, treatment was projected to enhance quality-adjusted survival by only 0.5 year.³⁴

Overtreatment would be expected if patients believe that treatment will lead to a much longer survival. Many studies have found that nearly every patient initially wants eradication of the cancer.⁹ In qualitative studies, some patients accepted side effects for any gain in survival but they were convinced that treatment would improve survival.⁹ Assuming that tumors would grow exponentially, urologists at the Mayo Clinic were also of the opinion that only 0.3% and 14.5% of screen-detected LPCs were “clinically insignificant.”³⁵ Patient anxiety caused by the new diagnosis of cancer and the consensus advice of specialists that LPC patients with a CALE of >10 years should choose treatment or be offered treatment⁶ will lead to high treatment rates. In 70% to 90% of patients, a treatment plan is usually made in a single visit to the urologist after a positive biopsy.³⁶

The mean Gleason grade of our patients was 6.6, and in 87% of patients the mean PSA was <10, both of which are low-risk categories but for which national guidelines recommend either observation or treatment.⁸ Only 12.5% of patients in our study chose observation. Specialists frequently recommend treatment even in low-risk patients because over 10 to 15 years the cancer may progress.²⁹ To manage this risk, a strategy of active surveillance with deferred initial treatment²⁸ is being increasingly recommended for patients at lower risk, ie, with cancers of Gleason grade <7, cancer stages T1c to T2a, and PSA <10. Almost half of patients with screen-detected cancer possess such characteristics.²⁷ In conjunction with specialists, primary care physicians (PCPs) can follow patients who

choose this strategy. PCPs may also offer more balanced advice because they might be more knowledgeable about the patient's preferences, comorbidities, and baseline CALE.³⁷ Patients with LPC may also want to review educational materials with their PCP. The American Cancer Society website was recommended because its content, accuracy, balance, and readability was rated the highest among 44 patient education materials about LPC.³⁸

Overtreatment can also be reduced with decreased screening, and several studies have shown that fewer patients want PSA screening if they are counseled before screening.³⁹ Enthusiasm for routine screening is high among specialists who treat LPC. In a random nationwide survey, 43% of 559 radiation oncologists recommended routine PSA screening in average-risk patients older than 80.⁶ Primary care physicians who frequently order PSA testing without much discussion about risks and benefits of testing cited reasons of lack of time, competing demands, limited patient health literacy, and fear of liability.⁴⁰ Prescreening counseling is difficult because it is unclear what and how much discussion should occur. As yet, we cannot say that screening or treatment can improve survival. The deleterious effects of treatment on urinary, bowel, and sexual dysfunction are better known; however, their frequencies and severities after different treatment techniques have been reported in more than 800 publications,⁴¹ vary greatly, and are difficult to balance. We can also share with patients that there is a small risk of immediate morbidity and mortality associated with prostate biopsy and cancer treatment; that a new anxiety results from a positive PSA test, whether or not it is followed by a negative biopsy; and that we cannot compare the risk of death caused by comorbid diseases with that of death caused by cancer without knowing the grade and stage of the cancer. However, patients must also know that, even if diagnosed with cancer, no randomized controlled trial has shown that treatment can or cannot improve survival in patients with screen-detected cancer. Interestingly, a study found that more African American patients wanted PSA screening after the use of a decision aid,³⁹ presumably because of the appreciation of the higher risk in African American patients.

In our patients, age, CALE, depression, and anxiety were the most important predictors of PDLO or PILT. Though PSA level also influenced

PDLO, PILT was related to social support. PDLO and PILT were not related to other factors such as race; income; education; health literacy; physical and mental summary SF-36 scores; urinary, bowel, and sexual symptoms; choice of treatment or observation; fear of cancer recurrence; functional capacity; and satisfaction with life, health, or with education by physicians in cancer treatment options. Although the association of PDLO and PILT with continuous depression scores was statistically significant, the importance of this finding is unclear given that 96.6% patients had a depression score of <7 , which indicates no depression.

Our findings may be difficult to generalize because our study sample was small. However, the differences we found between CALE and patient expectations of survival with and without treatment were large. Also, the mean age²⁶ and mean cancer grade²⁷ of patients newly diagnosed with LPC in large series and in our patients were similar. Our patients were treated by urologists in a private practice and more than 80% of urologists in the United States are in private practice.⁴² Our method of equating CCI scores with NCCN recommended health quartiles to estimate CALE is new and has not been previously validated. We used this method because we could not find any other validated method to estimate long-term health-adjusted life expectancy in individual ambulatory patients. Finally, we lost accuracy in the estimation of PDLO and PILT by asking patients to predict their survival in ordinal intervals rather than in a discrete number of years. We used ordinal intervals because it might be easier for patients to predict their survival this way, and the intervals allowed an estimation of PDLO and PILT of more than or less than 10 years.

Conclusion

In patients with newly diagnosed LPC, in whom the mean cancer grade was <7 and in whom education, income, and health literacy was intermediate to high, almost 38% of our patients had expectations of a reduction in survival of ≥ 10 years if they chose observation, and 48.8% patients expected an improvement in survival of ≥ 10 years through choosing treatment. These expectations are highly unrealistic because no study has shown that the cancer or its treatment can affect survival by even 1 year, especially in screen-detected patients with a cancer Gleason grade of <7 .

We thank Mr. Brian Main, Department of Urology, Eastern Virginia Medical School, for help with data entry and analysis.

References

1. Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. *J Clin Invest* 2007;117:2351–61.
2. Etzioni R, Penson D, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. *J Natl Cancer Inst* 2002;94:981–90.
3. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. *J Natl Cancer Inst* 2006;98:1134–41.
4. Harlan SR, Cooperberg MR, Elkin EP, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. *J Urol* 2003;170:1804–7.
5. Parker C, Muston D, Melia J, Moss S, Dearnely D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. *Br J Cancer* 2006;94:1361–8.
6. Fowler FJ, Collins MM, Albertsen PC, Zeitman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of localized prostate cancer. *JAMA* 2000;283:3217.
7. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. *Urology* 2002;60:258–63.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: prostate cancer. Available from http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed 25 January 2009.
9. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. *Cancer* 2006;106:1865–74.
10. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. *J Clin Oncol* 2005;23:2772–80.
11. Hu JC, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. *J Urol* 2003;169:2279–83.
12. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *J Clin Oncol* 2007;25:3576–81.
13. Wilson JRM, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life expectancy: how accurate are urologists and oncologists? *BJU Int* 2005;95:794–8.

14. Bass PF, Wilson JF, Griffith CH. A shortened instrument for literacy screening. *J Gen Intern Med* 2003;18:1036–8.
15. Hoffman RM, Stone SM, Espey D, Potosky A. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. *BMC Cancer* 2005;5:27.
16. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. *JAMA* 2001;285:2750–6.
17. Post PN, Hansen BE, Kil PJM, Coebergh JWW. The independent prognostic value of comorbidity among men aged <75 years with localized prostate cancer: a population-based study. *BJU Int* 2001;87:821–6.
18. Ware JE, Kosinski M. SF-36 Physical and Mental Health Summary Scales: a manual for users of version 1, 2nd ed. Lincoln (RI): QualityMetric, Inc.; 2005.
19. Litwin M, Hays RD, Fink A, Ganz PA, Leake B, Brooke RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care* 1998;36:1002–12.
20. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index). *Am J Cardiol* 1989;64:651–4.
21. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression scale. *Acta Psychiatr Scand* 1983;67:361–70.
22. Mehta SS, Lubeck DP, Pasta DJ, Litwin M. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaP-SURE. *J Urol* 2003;170:1931–3.
23. Sherbourne CD, Stewart AL. The MOS Social Support Survey. *Soc Sci Med* 1991;32:705–14.
24. Bowling A. Measuring health: a review of quality of life measurement scales, 2nd ed. Buckingham (UK): Open University Press; 1997.
25. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. *J Clin Oncol* 2004;22:2141–9.
26. Jang TL, Yossepowitch O, Bianco FJ, Scardino PT. Low risk prostate cancer in men under age 65: the case for definitive treatment. *Urol Oncol* 2007;25:510–4.
27. Draisma G, Boer R, Otto SJ, et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. *J Natl Cancer Inst* 2003;95:868–78.
28. Klotz L. Active surveillance for prostate cancer: for whom? *J Clin Oncol* 2005;23:8165–9.
29. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA* 2005;293:2095–101.
30. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. *JAMA* 2004;291:2713–9.
31. Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. *Can J Urol* 2004;11:2110–7.
32. Bill-Axelsson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med* 2005;352:1977–84.
33. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. *JAMA* 2006;296:2683–93.
34. Bhatnagar V, Stewart ST, Bonney WW, Kaplan RM. Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time. *Urology* 2004;63:103–9.
35. Dugan JA, Bostwick DG, Myers RP, Qian J, Bregstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. *JAMA* 1996;275:288–94.
36. Cohen H, Britten N. Who decides about prostate cancer treatment? A qualitative study. *Fam Pract* 2003;20:724–9.
37. Mohan R. Family physicians could help in predicting life expectancy without prostate cancer. *J Clin Oncol* 2008;26:690–1.
38. Fagerlin A, Rovner D, Stableford S, Jentoft C, Wei JT, Holmes-Rovner M. Patient education materials about the treatment of early stage prostate cancer: a critical review. *Ann Intern Med* 2004;140:721–8.
39. Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. *Am J Prev Med* 2007;33:428–34.
40. Guerra CE, Jacobs SE, Holmes JH, Shea JA. Are physicians discussing prostate cancer screening with their patients and why or why not? A pilot study. *J Gen Intern Med* 2007;22:901–7.
41. Visser A, van Andel G. Psychosocial and educational aspects in prostate cancer patients. *Patient Educ Couns* 2003;49:203–6.
42. American Urological Association. Member profile. October 2008. Available from <http://www.auanet.org/content/about-us/members/membersprofile.pdf>. Accessed 28 January 2009.